LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

MRK

106.76

+0.47%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

MRK

106.76

+0.47%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

MRK

106.76

+0.47%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

MRK

106.76

+0.47%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

MRK

106.76

+0.47%↑

Kodu・Aktsiate loetelu・AbbVie Inc

AbbVie Inc

Suletud

Sektor Tervishoid

188.97 1.46

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

186.13

Max

189.07

Põhinäitajad
By Trading Economics
Sissetulek	1M 1.4B
Müük	2.2B 14B
P/E Sektori keskmine	51.05 112.16
Aktsiakasum	2.65
Kasumimarginaal	9.474
Töötajad	50,000
EBITDA	514M 5B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+8.97 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. okt 2024
Järgmine dividendimakse kuupäev	15. nov 2024
Järgmine aktsia dividendi kuupäev (ex-date)	13. jaan 2025

Turustatistika
By TradingEconomics
Turukapital	-9.2B 338B
Eelmine avamishind	187.51
Eelmine sulgemishind	188.97

Uudiste sentiment

By Acuity

16%

84%

20 / 366 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

N/A / 195.0918 Toetus ja vastupanu

AbbVie Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. juuli 2024, 12:18 UTC

Tulu

AbbVie 2Q Revenue Gets Boost From Skyrizi, Rinvoq Sales

27. juuni 2024, 13:58 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Buys Celsius Therapeutics for $250 Million

26. apr 2024, 20:53 UTC

Suurimad hinnamuutused turgudel

AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q

26. apr 2024, 12:25 UTC

Tulu

AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises

3. sept 2024, 04:00 UTC

Peamised uudised

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

12. aug 2024, 14:30 UTC

Omandamised, ülevõtmised, äriostud

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12. aug 2024, 09:30 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Big Drugmakers Are Clinching Smaller Deals -- WSJ

1. aug 2024, 12:23 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Completes Acquisition Of Cerevel Therapeutics >ABBV CERE

29. juuli 2024, 10:30 UTC

Peamised uudised

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

25. juuli 2024, 13:01 UTC

Tulu

AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance -- IBD

25. juuli 2024, 12:46 UTC

Peamised uudised

Tulu

AbbVie Stock Is Rising on Strong Earnings. CEO Cites 'Significant Momentum.' -- Barrons.com

25. juuli 2024, 11:36 UTC

Tulu

AbbVie Sees FY Adj EPS $10.71-Adj EPS $10.91 >ABBV

25. juuli 2024, 11:36 UTC

Tulu

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25. juuli 2024, 11:36 UTC

Tulu

AbbVie 2Q EPS 77c >ABBV

25. juuli 2024, 11:36 UTC

Tulu

AbbVie 2Q Rev $14.46B >ABBV

25. juuli 2024, 11:36 UTC

Tulu

AbbVie 2Q Global Skyrizi Rev $2.73B >ABBV

25. juuli 2024, 11:36 UTC

Tulu

AbbVie 2Q U.S. HUMIRA Rev $2.36B >ABBV

25. juuli 2024, 11:36 UTC

Tulu

AbbVie 2Q International HUMIRA Rev $454M >ABBV

25. juuli 2024, 11:36 UTC

Tulu

AbbVie 2Q Adj EPS $2.65 >ABBV

25. juuli 2024, 11:36 UTC

Tulu

AbbVie 2Q Net $1.37B >ABBV

25. juuli 2024, 11:36 UTC

Tulu

AbbVie 2Q Global IMBRUVICA Rev $833M >ABBV

25. juuli 2024, 08:40 UTC

Peamised uudised

These Stocks Are Moving the Most Today: Ford, Tesla, Alphabet, Nvidia, Super Micro, IBM, ServiceNow, Chipotle, and More -- Barrons.com

27. juuni 2024, 13:28 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Acquires Celsius for $250 Million in Cash >ABBV

27. juuni 2024, 13:28 UTC

Omandamised, ülevõtmised, äriostud

AbbVie: Celsius' Lead Asset Has Completed Phase 1 Study in Inflammatory Bowel Disease >ABBV

27. juuni 2024, 13:26 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Acquires Celsius Therapeutics >ABBV

23. mai 2024, 20:05 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Completes Acquisition Of Landos Biopharma >ABBV LABP

7. mai 2024, 20:30 UTC

Peamised uudised

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

26. apr 2024, 13:03 UTC

Tulu

AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title -- IBD

26. apr 2024, 12:04 UTC

Tulu

AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop -- Barrons.com

26. apr 2024, 11:41 UTC

Tulu

AbbVie 1Q Adjusted EPS Cut 8c by Acquired IPR&D, Milestones Expense >ABBV

Võrdlus sarnastega

Hinnamuutus

AbbVie Inc Prognoos

Hinnasiht

By TipRanks

8.97% tõus

12 kuu keskmine prognoos

Keskmine 203.27 USD 8.97%

Kõrge 225 USD

Madal 170 USD

Põhineb 18 Wall Streeti analüütiku instrumendi AbbVie Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

18 ratings

Osta

Hoia

Müü

Põhineb 18 analüütiku instrumendi AbbVie Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 195.0918Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

20 / 366 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.